Abstract：
Little is known about the protection conferred by antibodies from natural human papillomavirus (HPV) infection. Our objective was to evaluate the association between HPV16 seroreactivity and HPV16 redetection, newly detected HPV infections, and loss of HPV DNA detection during follow-up. We analyzed data from 2462 unvaccinated Brazilian women. HPV16 IgG and neutralizing antibodies at baseline were assessed by enzyme-linked immunosorbent assay (n = 1975) and by the pseudovirus-based papillomavirus neutralization assay (n = 487). HPV detection, genotyping, and viral load were assessed by PCR-based methods. The associations were analyzed by Cox proportional hazards models. We observed a positive association between HPV16 IgG seroreactivity and redetection of HPV16 infections. Age-adjusted hazard ratios (HR) with 95% confidence intervals (CI) ranged from 2.45 (1.04-5.74) to 5.10 (1.37-19.00). Positive associations were also observed between HPV16 IgG antibodies and (1) newly detected HPV infections by genotypes unrelated to HPV16 (age-adjusted HR [95% CI] = 1.32 [1.08-1.2]) and (2) loss of detection of HPV infections by genotypes unrelated to HPV16 (age-adjusted HR [95% CI] = 1.24 [1.03-1.50]). Naturally developed HPV16 antibodies do not prevent recurrent HPV infections. Overall HPV16 IgG and neutralizing antibodies seem to be serological markers for latent or past infections.
摘要：
关于天然人乳头瘤病毒（HPV）感染的抗体赋予的保护作用知之甚少。我们的目的是评估HPV16血清反应性和HPV16再检测之间的关联，新发现的HPV感染，随访期间HPVDNA检测丢失。我们分析了2462名未接种疫苗的巴西妇女的数据。通过酶联免疫吸附测定（n=1975）和基于假病毒的乳头瘤病毒中和测定（n=487）评估基线时的HPV16IgG和中和抗体。HPV检测,基因分型，和病毒载量通过基于PCR的方法进行评估。通过Cox比例风险模型分析相关性。我们观察到HPV16IgG血清反应性与HPV16感染的重新检测之间存在正相关。年龄调整后的风险比（HR）与95％置信区间（CI）范围为2.45（1.04-5.74）至5.10（1.37-19.00）。在HPV16IgG抗体和（1）与HPV16无关的基因型新检测到的HPV感染（年龄调整后的HR[95％CI]=1.32[1.08-1.2]）和（2）与HPV16无关的基因型（年龄调整后的HR[95％CI]=1.24[1.03-1.50]）之间也观察到了正相关。自然开发的HPV16抗体不能预防复发性HPV感染。总体HPV16IgG和中和抗体似乎是潜伏或过去感染的血清学标志物。
